Trump's drugmaker deals may save economy $529B over 10 years, White House says
Summary
President Donald Trump’s agreements with major drug companies to lower U.S. prescription drug prices to levels similar to those in other wealthy countries could save the U.S. economy $529 billion over the next 10 years. The White House estimates these savings include government programs like Medicaid but has not yet released full details of the deals, which has raised skepticism among Democratic lawmakers.Key Facts
- The White House projects $529 billion in savings on U.S. prescription drug spending over the next decade due to Trump’s drug pricing deals.
- These deals require drugmakers to reduce U.S. prices to match prices paid in other developed countries.
- The savings include an estimated $64.3 billion for Medicaid, a government health program.
- The analysis comes from the White House Council of Economic Advisers and was shared with the Associated Press.
- Full terms of the agreements with 17 pharmaceutical companies have not been publicly disclosed.
- Democratic senators have proposed legislation to force the administration to release the deal details.
- The policy is called the “most favored nation” policy by Trump’s administration.
- Americans spent $467 billion on prescription drugs in 2024, highlighting the scale of potential savings.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.